Last reviewed · How we verify
Oxybutynin Cl
Oxybutynin Cl is a marketed drug by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Oxybutynin Cl |
|---|---|
| Also known as | Uromax |
| Sponsor | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- Treatment of Overactive Bladder With Anticholinergic Agents
- Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer (PHASE2)
- Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder (PHASE3)
- Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
- Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder (PHASE4)
- Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybutynin Cl CI brief — competitive landscape report
- Oxybutynin Cl updates RSS · CI watch RSS
- Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital portfolio CI